Milestone Scientific (NYSE:MLSS) said last week that chairman of the board Leslie Bernhard will take over as interim CEO after former president & CEO Daniel Goldberger resigned at the start of this month. The Livingston, N.J.-based company is conducting a formal search for a new CEO as the board of directors evaluates options for its CompuFlo […]
Featured
Ethics watchdog: Rep. Collins broke rules by advocating for biotech
There’s “substantial reason to believe” that Rep. Chris Collins (R-NY) broke federal law and congressional rules by sharing insider information to spur investment and by meeting with government researchers to advocate for Innate Immunotherapeutics (ASX:IIL) – an Australian biotech that he’s invested in. The Republican lawmaker recruited a number of investors for the company, including Dr. […]
Tandem prices $16m public offering
Tandem Diabetes Care (NSDQ:TNDM) today priced an underwritten public offering of 4,630,000 shares of its common stock, Series A warrants and Series B warrants to buy 4,630,000 shares of common stock at $3.50 apiece. The San Diego, Calif.-based company said it expects to bring in $16.2 million in gross proceeds from the offering. The offering’s Series […]
Nasdaq halts trading of Aerie stock as FDA reviews Rhopressa NDA
Aerie Pharmaceuticals (NSDQ:AERI) said today that Nasdaq has halted trading of the company’s common stock as an FDA committee convenes to review Aerie’s new drug application for its Rhopressa glaucoma and ocular hypertension drug. The Irvine, Calif.-based company submitted the NDA in February and the FDA is slated to finishing reviewing the application by Feb. 28, 2018. […]
Allergan settles Restasis patent challenge after moving patents to Native American tribe
Allergan (NYSE:AGN) said yesterday that it inked a deal with InnoPharma to settle a patent challenge over Allergan’s dry eye drug, Restasis. InnoPharma is one of four companies challenging Allergan’s patents to its eye drop product. The group also includes Mylan (NSDQ:MYL), Teva Pharmaceuticals (NYSE:TEVA) and Akorn Inc. (NSDQ:AKRX) – all of which are challenging the Restasis patents in […]
Biologics & auto-injectors: How West Pharma designs for evolving trends in drug delivery
If you’ve ever received a flu shot or taken insulin, you’ve probably used a device designed by West Pharmaceutical Services (NYSE:WST), according to VP & GM of biologics Graham Reynolds. “Probably most people have come in contact with West and they wouldn’t even know it,” he told Drug Delivery Business News. Over the 40 years he’s been […]
Sanofi invests $200m to expand France-based vaccine production facility
Sanofi (NYSE:SNY) plans to spend more than $200 million to expand a vaccine manufacturing site in Val de Reuil, France. The company said that the new facility will allow its global vaccines biz to expand its supply of VaxigripTetra, a quadrivalent flu vaccine, to up to 70 countries in six continents. “Influenza continues to be a major […]
Boehringer Ingelheim, Anthem partner for largest real-world COPD trial
As part of a research collaboration launched in 2014, Boehringer Ingelheim and Anthem have partnered to study people with chronic obstructive pulmonary disease in real-world settings to assess how commonly-prescribed drugs may reduce the occurrence of COPD exacerbations. The team, which also includes Anthem’s outcomes research subsidiary HealthCore, plans to investigate whether adding an inhaled […]
AcelRx shares tumble after FDA rejects Dsuvia painkiller
Shares in AcelRx Pharmaceuticals (NSDQ:ACRX) fell more than -50% this morning after the company announced that it received a complete response letter from the FDA for its Dsuvia sufentanil sublingual tablet. The FDA told the company that it can’t approve the new drug application in its present form, saying that AcelRx needs to collect additional data […]
European task force: Docs should favor drug-eluting stents over bioresorbable scaffolds
Physicians should not use bioresorbable scaffolds in place of current-generation drug-eluting stents, according to a report from the European Society of Cardiology and European Association of Percutaneous Cardiovascular Inventions. The ECS/EAPCI report says that as long as concerns remain about the increased risk of myocardial infarction and scaffold thrombosis linked with bioresorbable scaffolds, physicians should […]